Net Income

Dynatrace becomes a launch partner for Google's Gemini, embedding advanced observability directly into the next generation of agentic AI for developers and enterprises.

Avantor appoints financial heavyweight Simon Dingemans to its board, a strategic move to accelerate its ambitious turnaround amid market pressures.

Newly public AI firm Fusemachines unveils an ambitious 2026 growth plan, but faces significant financial hurdles and deep investor skepticism.

A new alliance led by engineering giant AtkinsRéalis will deliver the Midlands Rail Hub, a project promising vast economic growth and 300 extra trains daily.

Vancouver-based TRUBAR agrees to a C$201M buyout by Turkish food conglomerate ETİ Gıda, marking a major move in the booming plant-based snack market.

With trial data showing an average 23% body weight loss, Novo Nordisk's new combination drug CagriSema could usher in a powerful new era for medicine.

With a key drill target identified at its Rio Tinto-partnered project in Montana, the junior explorer is poised for a pivotal year in the hunt for copper.

Pharma giant GSK partners with biotech CAMP4, leveraging novel RNA-boosting tech to develop new therapies for neurodegenerative and kidney diseases.

Struggling Inno Holdings rolls the dice with a massive reverse stock split to avoid delisting, but grim financials and a brutal market reaction raise alarms.

After a challenging year marked by a mine fire and merger pains, Core Natural Resources is back online, signaling a major financial turnaround for 2026.

The neuro-focused biotech just acquired a late-stage cancer drug, securing massive funding. Is this a brilliant diversification or a high-stakes gamble?

Molecular Partners readies for a pivotal presentation at the J.P. Morgan conference, showcasing its next-gen DARPin therapeutics for hard-to-treat cancers.

Lincoln Gold secures $850k in a high-interest deal with its own chairman, funding Nevada projects but setting the stage for a shareholder vote on control.

Bolstered by positive clinical data and top investors, Kalaris Therapeutics extends its runway to advance TH103, a next-gen treatment for neovascular AMD.

Semrush's new app brings live marketing data directly into ChatGPT, promising a new era of efficiency and reshaping the competitive SaaS battleground.

With a pivotal FDA date set for June 2026, Achieve Life Sciences heads to the J.P. Morgan conference to discuss its promising anti-smoking drug.

The insurer's routine preferred stock dividend declaration masks a deeper story of record profits, strategic execution, and strong analyst confidence.

An international expert panel endorses an advanced wound therapy, potentially revolutionizing patient recovery and boosting a key player in the med-tech market.

Early Phase 1a data for Kalaris's new nAMD drug shows significant vision improvement and potential for extended durability, aiming to reduce patient burden.

A 120-day 'Cape to Cape' voyage introduces complimentary expedition adventures, setting a new standard for ultra-luxury world cruising.